Budesonide/formoterol combination in COPD: a US perspective.
Sharafkhaneh
Amir
A
Department of Medicine, Baylor College of Medicine, Houston, Texas 77030, USA. amirs@bcm.tmc.edu
Mattewal
Amarbir S
AS
Abraham
Vinu M
VM
Dronavalli
Goutham
G
Hanania
Nicola A
NA
D000280:Administration, Inhalation; D000305:Adrenal Cortex Hormones / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D058666:Adrenergic beta-2 Receptor Agonists / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000818:Animals; D001993:Bronchodilator Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D019819:Budesonide / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000069502:Budesonide, Formoterol Fumarate Drug Combination; D004338:Drug Combinations; D004983:Ethanolamines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D019317:Evidence-Based Medicine; D000068759:Formoterol Fumarate; D006801:Humans; D036501:Metered Dose Inhalers; D029424:Pulmonary Disease, Chronic Obstructive / Q000188:drug therapy*; D018570:Risk Assessment; D016896:Treatment Outcome; D014481:United States
D000305:Adrenal Cortex Hormones; D058666:Adrenergic beta-2 Receptor Agonists; D001993:Bronchodilator Agents; D000069502:Budesonide, Formoterol Fumarate Drug Combination; D004338:Drug Combinations; D004983:Ethanolamines; D019819:Budesonide; D000068759:Formoterol Fumarate
COPD exacerbations; bronchodilator; inhaled steroid; lung function; quality of life; β2-agonist